FibroTest (evaluation according to METAVIR system)

Fibrotest (Evaluation According To Metavir System)

We remind you that independent interpretation of the results is unacceptable, the information provided below is for reference purposes only.

Fibrotest is a non-invasive blood test used to assess the degree of liver fibrosis (scarring) in patients with chronic liver diseases, such as hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD). It is based on the Metavir scoring system, which evaluates the extent of fibrosis on a scale of F0 (no fibrosis) to F4 (cirrhosis).

Components and Interpretation

The Fibrotest is a combination of six serum markers: alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transferase (GGT), total bilirubin, and alanine aminotransferase (ALT). These markers are combined using a patented algorithm to provide a score ranging from 0 to 1, which correlates with the Metavir fibrosis stage.

The Fibrotest provides an estimate of the fibrosis stage, which can guide treatment decisions and monitoring. However, it should be interpreted in conjunction with other clinical data, such as liver enzyme levels, imaging studies, and liver biopsy results when available.

Role of FibroTest (Evaluation According to Metavir System)

FibroTest is a non-invasive blood test used to assess the degree of liver fibrosis, which is the formation of scar tissue in the liver due to chronic liver disease. It is based on the Metavir scoring system, a widely used method for staging liver fibrosis. FibroTest helps evaluate the extent of liver damage and monitor the progression of liver diseases, such as hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD).

Indications for FibroTest

FibroTest is recommended in the following situations:

• Diagnosis and monitoring of chronic liver diseases: FibroTest can aid in the initial diagnosis and ongoing monitoring of liver fibrosis in patients with chronic liver diseases, such as hepatitis C, hepatitis B, and NAFLD.
• Assessment of treatment response: FibroTest can be used to evaluate the response to treatment for chronic liver diseases, helping to determine if the treatment is effective in slowing or reversing the progression of fibrosis.
• Screening for liver fibrosis: FibroTest can be used as a screening tool for individuals at risk of developing liver fibrosis, such as those with metabolic syndrome, obesity, or excessive alcohol consumption.
• Follow-up after liver transplantation: FibroTest can be used to monitor liver fibrosis in individuals who have undergone liver transplantation, as they are at risk of developing recurrent liver disease.

Preparation for the Fibrotest (Evaluation According to Metavir System) Procedure

The Fibrotest (Evaluation According to Metavir System) procedure requires minimal preparation. However, there are a few recommendations to consider:

• Fasting: You may need to fast for 8-12 hours before the blood draw, depending on the specific instructions from your healthcare provider.
• Avoiding physical exertion: It is recommended to avoid strenuous physical activity for 24 hours before the test, as it may affect the results.
• Abstaining from alcohol and smoking: Refrain from alcohol consumption and smoking for at least 24 hours before the test, as these can influence the results.
• Hydration: Maintain adequate hydration levels to facilitate the blood collection process.
• Medication disclosure: Inform your healthcare provider about any medications you are taking, as some drugs may affect the test results.

The Fibrotest (Evaluation According to Metavir System) Procedure

The Fibrotest (Evaluation According to Metavir System) involves a simple blood draw, typically from a vein in the arm. A healthcare professional will perform the venipuncture, which usually takes a few minutes. Some minor bleeding or bruising may occur at the puncture site, but it should resolve within a few days.

Fibrotest (Evaluation According to Metavir System)

The Fibrotest is a non-invasive blood test used to assess the degree of liver fibrosis and cirrhosis. It is a patented test developed by BioPredictive, a French company, and is based on a combination of six serum markers: alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase (GGT), total bilirubin, and alanine aminotransferase (ALT). The test provides a score that correlates with the Metavir scoring system, which is a widely used method for staging liver fibrosis.

The Fibrotest is calculated using an algorithm that takes into account the levels of these six markers, along with the patient's age and gender. It is often used as an alternative to liver biopsy, which is an invasive procedure with potential complications. The Fibrotest can help determine the stage of fibrosis, monitor disease progression, and evaluate the response to treatment in patients with liver diseases such as chronic hepatitis C, chronic hepatitis B, and non-alcoholic fatty liver disease (NAFLD).

Sources:

https://www.sciencedirect.com/topics/medicine-and-dentistry/fibrotest
https://en.wikipedia.org/wiki/FibroTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198930/

IMPORTANT!

It is crucial to remember that the information provided in this section is not intended for self-diagnosis or self-treatment. If you experience any pain or worsening of a condition, it is essential to consult a healthcare professional for proper diagnostic tests and treatment. Only a qualified specialist can make an accurate diagnosis and determine the appropriate treatment. To obtain the most accurate and consistent assessment of test results, it is recommended to have them performed at the same laboratory. Different laboratories may use varying methods and units of measurement for similar tests, which could lead to inconsistent results.